Aim: Peritoneal metastases (PM) frequently occur in patients with gastric cancer and result in a poor prognosis. Exosomes play pivotal roles in tumor metastasis through the transfer of microRNAs (miRNAs). We examined the exosomal miRNA profile in peritoneal fluids to identify novel biomarkers to reflect tumor burden in the peritoneum.
| INTRODUC TI ON
The peritoneal cavity is the most frequent site of metastasis in gastric cancer and the outcome of patients with peritoneal metastasis (PM) of gastric cancer is still very poor. Although a combination of platinum agents plus fluoropyrimidine, taxane, or anthracyclines are generally used as first-line therapy for unresectable gastric cancer, 1 the efficacy of these systemic chemotherapy drugs for patients with PM is limited. 2, 3 Even after curative surgery, approximately half of patients with gastric cancer with serosal involvement (T4) have been reported to develop peritoneal recurrences. 4 Therefore, intensive adjuvant treatment to suppress peritoneal recurrence in high-risk patients is a key factor to improve the survival of patients with advanced gastric cancer.
Intraperitoneal chemotherapy (IPC) using taxane combined with systemic chemotherapy has shown marked clinical efficacy for gastric cancer with PM, and induction IPC followed by gastrectomy is supposed to be a promising strategy for this therapeutically challenging condition. 3 However, there is no reliable biomarker to assess the response of peritoneal lesions, which makes it difficult to determine the appropriate timing of conversion surgery or transition to second-line treatment.
Sensitivity of computed tomography (CT) scan for the detection of peritoneal metastases is limited even with modern techniques, because peritoneal metastases are often too small to be accurately evaluated for a reduction in size, 5 and thus accurate molecular biomarkers are necessary to assess tumor burden in the peritoneal cavity.
Exosomes /mL and size in nanometers). C, Exosome markers were confirmed by western blot analysis. CD9 and CD63 were detected in exosome fraction isolated from peritoneal fluids. Lane number indicates patient number. D, Quality and quantity of total RNA were evaluated by chip-based capillary electrophoresis. The electropherogram represents the size of distribution in nucleotides (nt) and fluorescence units (FU). RNA extracted from the exosome fraction mainly contains a small RNA fraction (< 200 nt) and a small amount of rRNA. Arrows indicate 18S and 28S rRNA subunits play pivotal roles in tumor metastasis formation 7 and that dysregulation of miRNAs is related to disease progression of gastric cancer. 8 In fact, exosomal miRNAs in blood can be used as non-invasive biomarkers for early diagnosis and evidence of tumor progression in various malignancies.
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In contrast, there is little information regarding miRNAs in peritoneal fluid. However, it is believed that large amounts of exosomes containing functional miRNAs are released into the peritoneal cavity before the formation of PM, and thus analysis of the miRNA profile in peritoneal exosomes should provide important information to develop adequate treatment of PM. In the present study, therefore, we tried to identify novel biomarkers that can reflect the volume of PM using the expression analysis of miRNAs in exosomes derived from peritoneal fluids of patients with gastric cancer.
| MATERIAL S AND ME THODS

| Patients and sample collection
The study protocol was approved by the Bioethics Committee for 
| Isolation of extracellular vesicles and
RNA extraction
Peritoneal fluid samples were centrifuged at 2000 g for 10 minutes to remove floating cells. Supernatants were filtered through an 800-nm filter (Millipore, Burlington, MA, USA) to remove cell debris and ultracentrifuged at 150 000 g for 70 minutes at 4°C. Presence of isolated EV were confirmed using an HT-7700 transmission electron microscope (Hitachi High-Technologies, Tokyo, Japan). Size distribution and number of EV were determined using NanoSight LM10 (Malvern, Amesbury, UK). RNA extraction was carried out using an miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Total RNA in the samples were assessed for quantities and quality using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 
| Western blot analysis
TA B L E 2 (Continued)
F I G U R E 2 Expression of microRNA (miR)-21-5p, miR-92a-3p, miR-223-3p, and miR-324-3p in exosomes derived from peritoneal fluid of patients with gastric cancer patients with various pathological T (depth of invasion) stages. Peritoneal metastases (PM) means cases with macroscopic (P1) or microscopic peritoneal metastasis (P0CY1). Expression of miRNAs was determined with TaqMan Advanced miRNA assays and relative expression levels were calculated against average of miR-10a-5p and miR-30d-5p. *P < .05 transferred to PVDF membranes (Invitrogen), and immunoblotted with the following primary antibodies: CD9 Reagents (GE Healthcare) and imaged using LAS-3000 mini (Fujifilm Life Science, Tokyo, Japan).
| miRNA expression analysis
To determine miRNAs expressed in peritoneal fluid, comprehensive miRNA expression analysis was carried out using miScript SYBR 
used to explore the most stably expressed miRNAs in samples with or without PM. The Ct values were normalized with the miRNAs selected from the NormFinder algorithm and subsequently used for delta-delta-Ct calculation method.
Next, expressions of candidate miRNAs were validated in all 58 samples using TaqMan Advanced miRNA Assays (ThermoFisher Scientific). For the quantitative PCR reaction, 500 pg total RNA was used to prepare cDNA templates from miRNA followed by PCR amplification of the cDNA template using TaqMan
Advanced miRNA cDNA Synthesis Kit (ThermoFisher Scientific).
Quantitative PCR reactions were carried out, and the relative expression level was calculated using normalizer similar to the previous experiment.
| Statistical analysis
Difference between categorical variables was evaluated using chi- F I G U R E 4 Expression levels of microRNA (miR)-29a-3p, miR-29b-3p and miR-29c-3p in peritoneal metastases (PM) (+) and PM (−) patients (Upper) and in 24 patients with T4 tumors who showed peritoneal recurrences after curative gastrectomy (n = 6) and in those who did not (n = 18) (Lower). P values were evaluated with the Wilcoxon test. *P < .05, **P < .01, ***P < .001; ns, not significant (138.5-1292.0) pg/μL and 687.2 (179.0-3133.1) pg/μL, respectively ( Figure 1D ).
| Identification of miRNAs expressed in peritoneal fluids
In the initial screening phase, we combined the 11 samples from patients with PM and the 14 samples from patients without PM, explored miRNA profiles using miRNome PCR array, and identified 56 and 54 stably expressed miRNAs, respectively (Data S1). Based on this result, a total of 56 miRNAs were selected as candidate miRNAs, and quantified in each sample using a custom PCR array. Using the NormFinder algorithm, we identified the most stably expressed miRNAs and miR-30d-5p and miR-10a-5p which were selected as internal controls. Then, eight and three miRNAs were significantly up-and downregulated in samples with PM, respectively ( Table 1 ).
| Four miRNAs (miR-21-5p, miR-92a-3p, miR-223-3p, and miR-342-3p) reflect the progression of peritoneal metastasis
As validation analysis, we examined the expressions of these dysregulated miRNAs in a total of 58 patients with various stages of gastric cancer ( Table 2 ). In 12 patients with PM, 10 patients showed macroscopic metastasis (P1) and two patients had microscopic metastasis (P0CY1). A type 4 tumor with undifferentiated histology was more frequently included in the PM (+) group. Among the eight upregulated miRNAs, miR-21-5p, miR-92a-3p, miR-223-3p, and miR-342-3p
were expressed significantly higher in 12 patients with PM compared to those without PM (P < .05) (Figure 2 ). Among the patients without PM, levels of these miRNAs tended to be higher in cases with pathological serosal exposure (pT4) with significant difference in miR-21-5p (P < .05) (Figure 2 ). Moreover, among the 12 patients with PM, their expression levels showed positive correlation with PCI score which is generally used to assess the extent of peritoneal cancer throughout the peritoneal cavity (Figure 3 ).
| miR-29 family is downregulated in exosomes in peritoneal fluids with PM and associated with peritoneal recurrence in patients with T4 gastric cancer
Next, we examined the miR-29 family which was downregulated in PM (+) patients in the screening phase. As shown in Figure 4 (Table 3) . Interestingly, however, the expression levels of miR-29b-3p in peritoneal exosomes obtained at surgery were miR-29a-3p and miR-29c-3p also showed a similar trend although the differences were not statistically significant. When the patients were divided into two groups based on median levels of miR-29b-3p, patients with low miR-29b-3p expression showed significantly worse peritoneal recurrence-free survival (P < .05) and worse trend in overall survival ( Figure 5 ).
| D ISCUSS I ON
Despite recent vigorous studies on exosomes, little information is available regarding the miRNA profile in peritoneal exosomes.
In the present study, we tried to isolate exosomes from peritoneal fluid from patients with gastric cancer and found candidate miRNA species related to peritoneal dissemination. Morphological and nanotracking analysis showed that EV obtained by ultracentrifugation consisted mostly of exosomes, which is consistent with a previous study on various body fluids such as breast milk, serum, plasma, and urine.
11
With comprehensive analysis using PCR arrays, we identified 11 exosomal miRNAs that were dysregulated in samples from patients with PM. As no reference miRNA is valid for every experimental design, it should be assessed in each experiment. In this study, we selected miR-10a-5p and miR-30d-5p as reference miRNAs among several stably expressed miRNAs based on NormFinder analysis in an exploratory data set. 10 Among them, we confirmed that the expression levels of four miRNAs (miR-21-5p, miR-92a-3p, miR-223-3p, and miR-324-3p) evaluated with TaqMan probe methods were significantly elevated in a validation series with 58 patients. Furthermore, in patients with PM, their expression levels showed positive correlation with PCI score. This strongly suggests that these exosomal miRs are preferentially produced from tumor cells and thus reflect the total tumor burden in the peritoneal space.
Among the four miRs, miR-21-5p is the most commonly upregulated in various solid cancers and high expression of miR-21-5p was related to worse clinical outcomes. 12, 13 In a systematic review, miR-21-5p was the most consistently reported to be upregulated in gastric cancer tissues compared with those in noncancerous gastric tissues.
14 Recently, Tokuhisa et al have used a similar approach and identified five miRNAs upregulated in malignant ascites. 15 In their study, miR-21-5p was significantly elevated in samples from patients with PM, and were significantly higher in patients with T4 tumor than in those with T1 to T3 tumors, which is totally consistent with our results.
Previous studies have shown that miR-223-3p and miR-92a-3p
are also upregulated in gastric cancer tissue 14, 16 and serum of patients with gastric cancer. 17 miR-342-3p expression has been shown to be upregulated in colon cancer tissue, 18 although no data are available on gastric cancer. More importantly, miR-21-5p and miR-223-3p
have been reported to promote invasion of gastric cancer cells. 19, 20 These results suggest a possibility that gastric cancer, once it has invaded the serosal surface, releases exosomes including these oncomiR into the peritoneal cavity, which may assist the progression of peritoneal tumor. In summary, we examined exosomes contained in peritoneal fluids and identified four miRNAs which were upregulated and appeared to reflect tumor burden in the peritoneum. Periodical quantification of these exosomal miRNAs may be useful to determine the response to chemotherapy and select the appropriate treatment for patients with PM of gastric cancer. Reduced expression of miR-29 in peritoneal exosomes is a strong risk factor for developing postoperative peritoneal recurrence in patients who underwent curative surgery for T4 gastric cancer. miR-29b-3p might be a novel target to prevent peritoneal recurrence in these patients. The clinical relevance of these exosomal miRNAs should be validated in larger cohorts.
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